What FDA guidance is
FDA guidance documents describe the agency’s current thinking on a regulatory topic. They are governed by FDA’s Good Guidance Practices rule, 21 CFR 10.115. The rule is explicit: guidance documents “do not establish legally enforceable rights or responsibilities.” You may use another approach if it satisfies the statute and regulations. FDA staff, by contrast, may depart from guidance only with justification and supervisory concurrence.
The rule sorts guidance into two levels:
- Level 1 covers first interpretations, more-than-minor policy changes, complex science, and controversial issues. These are normally published as drafts for comment before being finalized.
- Level 2 covers existing practice or minor changes. These are usually implemented on posting, with comments invited afterward.
Every guidance must say it is nonbinding, show its issue date, and, if it is a draft, contain the word “draft.” Those markers matter a great deal once guidance is fed into an AI system.
Recent example. In October 2024 FDA finalized Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers. It builds on the 1997 Part 11 rule and the 2003 scope-and-application guidance, with 29 questions covering risk-based validation, audit trails, digital health technologies, IT service providers, and e-signatures. It is a good case study: earlier drafts (2017 and 2023) still circulate, and an AI tool that retrieves the draft rather than the final text will give outdated answers.
Where to find it
- Search for FDA Guidance Documents on fda.gov: filter by product area, issue date, topic, and draft or final status.
- The Federal Register carries notices of availability for Level 1 guidance and opens the comment docket.
- Regulations.gov holds the comment dockets, useful for understanding why a final version changed.
Reuse terms
FDA’s Website Policies say that information on fda.gov is in the public domain and may be copied and distributed unless otherwise noted. The “unless otherwise noted” part is where our conditional rating comes from:
- Third-party material. Guidance may quote or reproduce copyrighted standards, figures, or tables. Those keep their own rights.
- Logos and endorsement. Public domain text does not let you imply FDA endorses your product or AI tool.
- Status. A draft is FDA’s proposal, not its current thinking for implementation. Reusing a draft as if final is a substance problem, not a copyright one.
Using FDA guidance in AI and RAG
- Store the PDF from fda.gov, not a copy from a blog or vendor site. Record the URL, docket number, issue date, and the date you downloaded it.
- Tag every file as Draft or Final, and keep superseded versions in a separate archive index rather than the live one.
- Keep the nonbinding statement with the chunks. If your chunking drops the boilerplate, add a metadata field so answers can say “FDA recommends” rather than “FDA requires.”
- Link guidance to the regulation it interprets. A Part 11 question should retrieve both 21 CFR Part 11 and the 2024 Q&A guidance, with the regulation shown as the binding layer.
- Flag embedded third-party content (for example, excerpts of consensus standards) so it is not quoted at length in outputs.
- Re-check the guidance list on a schedule. FDA withdraws, revises, and finalizes documents throughout the year.
Common mistakes
- Treating “should” in guidance as “must.” Only the statute and regulations carry “must,” and guidance uses mandatory words only when describing those requirements.
- Indexing a draft and a final version together without status tags, so the model blends them.
- Assuming public domain covers everything inside a PDF, including copyrighted figures.
- Citing a guidance without its date, which makes later audits of AI answers impossible.
Checklist
- Source PDF downloaded from fda.gov, with URL and download date logged
- Draft or Final tag on every file and chunk
- Superseded versions moved to an archive index
- Nonbinding status preserved in metadata
- Third-party content flagged
- Linked to the regulation it interprets
- Refresh schedule set (for example, monthly)
How AskDona helps
AskDona checks your SOPs, validation records, and submissions against the FDA guidance you choose, and every finding points to the exact paragraph it relied on. Because each source carries its status and date, reviewers can see at a glance whether an answer rests on a final guidance, a draft, or the regulation itself.
Run a sample gap check against an FDA guidance
AskDona shows the evidence; your regulatory team decides.
Editor’s note. This article is general information, not legal advice. The “conditional use” rating comes from our source list and is a first-pass judgment, not a legal opinion. Check the notes on each guidance before reuse.
FAQ
Is FDA guidance legally binding? No. Under 21 CFR 10.115(d), guidance does not create enforceable rights or duties. In practice, departing from it means you should be ready to show your alternative meets the regulation.
Can I put FDA guidance PDFs into a commercial AI tool? Generally yes for FDA-authored text, since fda.gov content is public domain unless noted. Check each document for third-party material and do not imply FDA endorsement.
Should drafts be in my RAG index at all? They can be useful to show where FDA is heading, but label them clearly and keep them out of answers about current expectations unless the user asks.
How do I know a guidance is still current? Check the FDA guidance search for its status and look for a later final or revised version.
References
All pages opened and checked by October 26, 2026.
| Source | What it supports |
|---|---|
| 21 CFR 10.115, Good Guidance Practices (LII) | Nonbinding status, Level 1 and 2, draft labeling, required elements |
| FDA Website Policies | Public domain status of fda.gov content, unless otherwise noted |
| Search for FDA Guidance Documents | Where to find guidance and filter by status |
| Cooley: FDA Finalizes Guidance on Part 11 in Clinical Investigations (Oct 24, 2024) | October 2024 final Part 11 Q&A guidance and its scope |